WO2006005074A2 - Novel hot start nucleic acid amplification - Google Patents
Novel hot start nucleic acid amplification Download PDFInfo
- Publication number
- WO2006005074A2 WO2006005074A2 PCT/US2005/023824 US2005023824W WO2006005074A2 WO 2006005074 A2 WO2006005074 A2 WO 2006005074A2 US 2005023824 W US2005023824 W US 2005023824W WO 2006005074 A2 WO2006005074 A2 WO 2006005074A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- binding protein
- stranded nucleic
- temperature
- primer
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 54
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 53
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 53
- 230000003321 amplification Effects 0.000 title claims abstract description 25
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 25
- 101710088729 Single-stranded nucleic acid-binding protein Proteins 0.000 claims abstract description 229
- 238000006243 chemical reaction Methods 0.000 claims abstract description 189
- 238000000034 method Methods 0.000 claims abstract description 86
- 239000000203 mixture Substances 0.000 claims abstract description 86
- 239000011541 reaction mixture Substances 0.000 claims abstract description 66
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 4
- 238000009396 hybridization Methods 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 27
- 230000000295 complement effect Effects 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 238000011534 incubation Methods 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 15
- 238000004925 denaturation Methods 0.000 claims description 14
- 230000036425 denaturation Effects 0.000 claims description 14
- 230000003993 interaction Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 150000001768 cations Chemical class 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 description 78
- 108020004414 DNA Proteins 0.000 description 75
- 238000003752 polymerase chain reaction Methods 0.000 description 75
- 108010006785 Taq Polymerase Proteins 0.000 description 53
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 42
- 101710093976 Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 39
- 235000019527 sweetened beverage Nutrition 0.000 description 39
- 102000053602 DNA Human genes 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 239000012536 storage buffer Substances 0.000 description 22
- 239000000872 buffer Substances 0.000 description 21
- 230000027455 binding Effects 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 12
- 230000037452 priming Effects 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000006820 DNA synthesis Effects 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001351 cycling effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 5
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 5
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 5
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 5
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 5
- 239000005547 deoxyribonucleotide Substances 0.000 description 5
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000007849 hot-start PCR Methods 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000009919 sequestration Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000701832 Enterobacteria phage T3 Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 101710176276 SSB protein Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000008049 TAE buffer Substances 0.000 description 3
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 108700014590 single-stranded DNA binding proteins Proteins 0.000 description 3
- 101150112274 ssb gene Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- -1 hi addition Proteins 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 108010005008 single stranded DNA dependent ATPase Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 108030003004 Triphosphatases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000027832 depurination Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Definitions
- the present invention provides a method that reduces or eliminates nonspecific primer extension products. More specifically, the method uses single-stranded nucleic acid binding proteins to reduce or eliminate these products. This invention is contemplated to be especially useful as a novel Hot Start method for the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- nucleic acids are duplicated or replicated through coordinated, catalytic synthesis.
- nucleic acid amplification occurs through a process of hybridizing (annealing or pairing) a relatively short single-stranded nucleic acid (primer or oligonucleotide), to a relatively longer single-stranded nucleic acid counterpart (target or template) that has complementary nucleic acid sequence.
- Complementary annealing refers to the base pairs which form and are stabilized by hydrogen bonds described by Watson-Crick pairing rules (i.e., A-T and G-C base pairs).
- a polymerase can use this hybrid (or complement) to catalytically add bases or nucleotides which are present in the reaction to the 3' end of the primer. The nucleotides are added such that they are complementary to the target or template.
- primer extension Since the newly synthesized strand of nucleic acid is the result of nucleotides which extend the length of the primer, this process is also known as primer extension. To be extended by a polymerase, a primer strand first must be annealed to a template strand.
- primer extension products are designed to be complementary to a specific portion of the template strand, under certain conditions the primer can and will anneal to other regions of the template strand with which it is only partially complementary, or in rare cases, noncomplementary.
- a fully complementary pairing is referred to as and is the result of specific priming and a partially complementary (or noncomplementary) pairing is referred to as and is the result of nonspecific priming. Since the polymerase cannot discriminate between partial versus full complements, primer extension products can and will be formed from both if both are present under extension conditions.
- primer extension products from full complements are referred to as specific products and those from partial (or non-) complements are referred to as nonspecific products.
- T m melting temperature
- T n the melting temperature
- the temperature of the hybridization reaction determines the amount of specific versus nonspecific priming based on thermodynamic principles. Temperatures significantly below the T m will permit nonspecific priming while temperatures significantly above the T m will restrict nonspecific and specific priming (e.g., Gillam et al., 1975, Nucleic Acids Research 2(5):625-634; Wallace et al., 1979, Nucleic Acids Research 6(ll):3543-3557).
- hybridization is carried out at or near the T m of the primer(s) to generate specific complements and thus specific primer extension products.
- hybridization and primer extension temperatures significantly lower than the T m of the primers are referred to as permissive or nonstringent while temperatures at or near the T m are referred to as restrictive or stringent.
- permissive or nonstringent temperatures lead to nonspecific primer extension products while restrictive or stringent temperatures lead to specific ones.
- a well-known example of primer extension is the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- DNA synthesis occurs in a series of steps comprising a cycle, this cycle being repeated many times to amplify the primer extension reaction products for further analyses.
- Two primers typically are used in which their respective 3 '-ends face one another to generate a double-stranded DNA product whose length is defined as the distance between the primers.
- the cycle consists of a step which generates single-stranded DNA 3 a step which allows primers to hybridize with their target sequences, and a subsequent step for primer extension by the polymerase.
- the PCR technique is described in detail in U.S. Pats. Nos. 4,683,202; 4,683,195; and 4,965,188.
- RNA is used as a template in the reaction instead of DNA.
- reverse transcription-PCR reverse transcription-PCR
- an initial step of converting the RNA template to DNA is performed with a polymerase which has reverse transcriptase activity.
- reverse transcription step reactions proceed as in standard PCR.
- thermostable polymerases such as the polymerase from Thermus aquaticus (Taq DNA Polymerase) allows the use of more stringent reaction temperatures (Chien et al., 1976, Journal of Bacteriology 127(3):1550-1557; Saiki et al., 1988, Science 239(4839):487-491). Stringent hybridization temperatures increase the probability of generating specific products.
- temperatures used during the polymerase chain reaction can be stringent, the reaction mixtures themselves are not conveniently assembled at higher temperatures, temperatures at which greater priming specificity occurs.
- PCR reactions are usually assembled at lower temperatures such as on ice or most preferably at room temperature (i.e., 20-25 0 C). If the average primer can be assumed to have a T m of about 50- 60°C, the temperatures at which reaction set-up occur are clearly significantly lower and will favor nonspecific priming.
- the conventional polymerases used in the PCR e.g., Taq DNA Polymerase
- Another method is to use an antibody that non-covalently binds to the polymerase and prevents its activity at lower temperatures. At higher temperatures, the non- covalent bond between the antibody and the polymerase is disrupted and polymerase activity is restored for the rest of the PCR reaction.
- This method is further described in U.S. Pat. No. 5,338,671. Although this method is effective, the production process for generating the antibody is expensive and can introduce contaminating mammalian genomic DNA into the PCR reaction.
- Yet another technique involves covalent attachment of a chemical moiety to the polymerase which blocks its activity at lower temperatures. This covalent bond can be broken after significant heating (e.g., above 95°C for about 10-15 minutes) after which the polymerase activity is restored.
- a variety of chemical modifications can be introduced to produce the polymerase-moiety complex required to practice this technique as described in U.S. Pats. Nos. 5,677,152, 6,183,998 and 6,479,264.
- This technique has the disadvantage of requiring an extensive initial heating step which can damage DNA through heat-induced depurination. Such an extensive heating step also markedly reduces the activity of the polymerase relative to standard PCR methods.
- primer extension reactions can be defined by two key events. One, the process of hybridizing the primer to the template and two, the extension of the hybrid by the catalytic action of a polymerase.
- the specificity of the hybridization is governed by the principles of thermodynamics in which lower temperatures favor nonspecific priming and amplification artifacts. Because polymerase chain reactions are conventionally assembled at lower temperatures, amplification artifacts can be a problem.
- Various methods have been developed to address this problem, techniques known as hot-start PCR.
- the present invention is a novel method of hot-start PCR.
- a method of duplicating a template nucleic acid, or a portion thereof, is provided wherein a primer having a nucleotide sequence that is complementary to a target portion of the template nucleic acid is hybridized to the template nucleic acid and then extended via an enzyme.
- the method includes the following steps: (a) at a first temperature, preparing a reaction mixture including a primer, a template nucleic acid, an enzyme effective to catalyze primer extension and an effective amount of single-stranded nucleic acid binding protein, (b) at a second temperature higher than the first temperature, carrying out a hybridization reaction to produce a hybridized product, and (c) at a third temperature higher than the first temperature, carrying out a primer extension reaction to produce from the hybridized product an extended product; wherein the generation of specific extended product is improved as a result of incorporating the single-stranded nucleic acid binding protein into the reaction mixture at the first temperature.
- a primer complex also is provided.
- the complex includes a primer having a nucleotide sequence that is complementary to a specific target portion of a template nucleic acid molecule, and a single-stranded nucleic acid binding protein interacting with the primer.
- the single-stranded nucleic acid binding protein is selected such that 1) it in effect inhibits the primer from participating in a primer extension reaction up to at least a first temperature at or below 30 0 C, and 2) that interaction ceases or is disrupted at a second temperature in the range of 30 0 C to about 72°C such that the primer is substantially uninhibited by the single- stranded nucleic acid binding protein from participating in a primer extension reaction at the second temperature.
- a PCR reaction mixture also is provided, including a primer having a nucleotide sequence that is complementary to a specific target portion of a template nucleic acid, and a single-stranded nucleic acid binding protein effective to inhibit the primer from participating in a primer extension reaction up to at least a first temperature at or below 30 0 C, wherein the inhibitive capability of the single-stranded nucleic acid binding protein is lost at a second temperature in the range of 30 0 C to about 72°C.
- Figure 1 is an agarose gel electrophoresis image illustrating the effectiveness of hot-start methods using single-stranded DNA binding proteins according to the disclosed methods, compared to other methods as described in Example 1.
- Figure " 2 is an agarose gel electrophoresis image illustrating the effectiveness of hot-start methods using a mixture of wild-type and the ⁇ 26C mutant of T7 SSB, T7 gp2.5- ⁇ 26C, as described in Example 2.
- Figure 3 a is a schematic of the polymerase blocking assay of Example 3.
- the forward primer has a HEX label attached to its 5 'end to allow fluorescent detection.
- the primer extension product is a 27 base addition to the 23-base forward primer.
- the observed change during denaturing PAGE is from 23 to 50 bases.
- Figure 3b is a denaturing, polyacrylamide gel electrophoresis image illustrating the blocking effects of a mixture of wild-type and the ⁇ 26C mutant of T7 SSB in the mock PCR reaction described in Example 3.
- Figure 4 is an agarose gel electrophoresis image illustrating a range of concentrations of wild-type T7 SSB that are effective in a hot-start method as herein described, Example 4.
- a 'single-stranded nucleic acid binding protein' is a polypeptide or protein that exhibits very high affinity for interacting with (i.e., binding) single-stranded nucleic acids.
- a single-stranded nucleic acid binding protein exhibits a higher affinity for and preferentially binds to single-stranded nucleic acids over double-stranded nucleic acids.
- SSBs can bind to a single-stranded molecule or fragment of DNA or RNA, but generally a specific type of SSB prefers one to the other.
- SSB proteins discussed herein have a higher affinity for DNA than for RNA, and are more often referred to as single-stranded DNA binding proteins in the scientific literature.
- SSBs bind to single-stranded nucleic acids stoichiometrically, which means that they bind in approximately fixed molar ratios with respect to the nucleic acid, hi addition, SSBs generally bind nucleic acid with no sequence specificity (i.e., without regard to the base composition of the nucleic acid).
- the SSBs referred to herein are not enzymes, meaning they do not exhibit any substantial (or known) enzymatic activity (Chase and Williams, 1986, Annual Reviews of Biochemistry 55:103-136).
- the term 'hybridization' refers to the bonding of one single-stranded nucleic acid to another single-stranded nucleic acid, such as a primer strand to a template strand, via hydrogen bonds between complementary Watson-Crick bases in the respective single-strands to thereby generate a double-stranded nucleic acid hybrid or complex as otherwise known in the art.
- the terms 'hybridize,' 'anneal,' and 'pair' are used interchangeably in the art to describe this reaction, and so too they are used interchangeably herein.
- Hybridization may proceed between two single-stranded DNA molecules, two single-stranded RNA molecules, or between single-strands of DNA and RNA, to form a double-stranded nucleic acid complex.
- 'denaturation' means the process of separating double-stranded nucleic acids to generate single-stranded nucleic acids. This process is also referred to as 'melting'.
- the denaturation of double-stranded nucleic acids can be achieved by various methods, but herein it principally is carried out by heating.
- 'single-stranded DNA' will often be abbreviated as 'ssDNA'
- the term 'double-stranded DNA' will often be abbreviated as 'dsDNA'
- the term 'double-stranded RNA' will often be abbreviated as 'dsRNA'. It is implicit herein that the term 'RNA' refers to the general state of RNA which is single-stranded unless otherwise indicated.
- an SSB is said to 'interact' or to be 'interacting' with a primer when it cooperates with, or otherwise is correlated, associated, coupled or otherwise complexed to, the primer in such a manner so as to substantially inhibit or prevent the primer from participating in a primer extension reaction.
- the term 'interact' and variants thereof is/are considered to include, but not necessarily to be limited to, a chemical bond (covalent, non-covalent or otherwise) as well as other modes of binding or bonding that are or may be achieved between an SSB and its associated primer so as to produce the primer extension- inhibitive effect described in this paragraph, and further described herein as well as observed in the following Examples.
- the present invention provides methods and reagents that inhibit or prevent the generation of nonspecific primer extension products that result from nonspecific priming events at permissive temperatures.
- the methods are envisioned to be particularly useful and applicable to primer extension via the polymerase chain reaction (PCR) although the invention is not limited to such reactions.
- PCR polymerase chain reaction
- the present invention is applicable to any reaction or process incorporating otherwise conventional hybridization and primer extension reactions to produce an amplified or newly synthesized double-stranded product from a primer- template hybrid, whether as an intermediate or final product.
- the present invention would also be useful for the variation of PCR called reverse transcription-PCR in which a reverse transcription step converts RNA to DNA.
- Other examples of primer extension reactions include DNA and RNA sequencing, reverse transcription, in vitro transcription and isothermal amplification, among others.
- PCR mixtures usually are prepared or assembled at room temperature (less than 30°C, more typically 20-25 0 C) or on ice (O 0 C) in reaction tubes suitable for accommodating the hybridization and primer extension reactions in a conventional thermal cycler. Nearly, if not entirely, all PCR mixtures initially are prepared below 37°C.
- a typical PCR mixture will include at least the following essential components:
- a template nucleic acid which can be single-stranded or double-stranded, which it is desired to amplify
- At least one primer that is complementary to a target portion of the template nucleic acid if the template is double-stranded and it is desired to amplify both strands then at least two primers will be provided, each being complementary to a specific target portion on each of the sense and anti-sense template strands;
- dATP deoxyribonucleotides necessary for enzyme-directed nucleic acid synthesis
- exogenous nucleotides may be included as well (e.g., dUTP);
- an enzyme or enzymes for directing nucleic acid synthesis typically a polymerase such as Taq DNA polymerase and/or other thermostable polymerases, reverse transcriptase (e.g., MMLV-RT or AMV-RT) or other suitable enzyme if template is RNA;
- a polymerase such as Taq DNA polymerase and/or other thermostable polymerases, reverse transcriptase (e.g., MMLV-RT or AMV-RT) or other suitable enzyme if template is RNA;
- a polymerase(s) is used, a divalent cation such as Mg 2+ , Mn 2+ , etc., which is an accessory for polymerase activity;
- all of the foregoing essential components can be assembled together in the reaction mixture at room temperature, along with an effective amount of a SSB(s) as hereinafter described, yet nonspecific primer extension products are inhibited or prevented from occurring at nonstringent temperatures such as room temperature.
- a SSB(s) as hereinafter described
- other components which are known or conventional in the art also can be included in the reaction mixture to achieve various known or conventional effects, e.g., glycerol, betaine, DMSO, detergents, etc., the selection and incorporation of which are within the ability of one having ordinary skill in the art.
- the tubes can be transferred to a thermal cycler to carry out the cyclic reactions for automated PCR. Less preferably, manual PCR can be used.
- a preferred PCR temperature profile contemplated herein is disclosed in Table 1.
- a te nuc 1 lei-c aci -di can vary, generally Polymerase extends primer thereby
- the Initial Denaturation step is carried out to heat-denature double-stranded template strands, and is not repeated as a part of the cycle.
- the cycle which is repeated many times consists of the following steps.
- the Denaturation step which is conventionally shorter in duration than the Initial Denaturation step
- dsDNA is heat-denatured to generate ssDNA which can be annealed in the subsequent step.
- the primer and template strands are annealed at a stringent temperature so as to produce, preferentially, a specific hybridization product, as compared to a nonspecific hybridization product which would result if hybridization were carried out at a lower, nonstringent temperature.
- a primer extension reaction is carried out at a temperature that preferably has been optimized for the particular enzyme or enzymes being used to catalyze the primer extension reaction.
- the foregoing cycle of steps is repeated many times (e.g. 25-45 times) to generate an amplified double-stranded primer extension product.
- RNA-dependent, DNA polymerase reverse transcriptase
- This enzymatic conversion can be accomplished by a thermostable polymerase other than Taq DNA Polymerase (e.g., Tth DNA Polymerase) or more commonly by less thermostable polymerases such as MMLV-RT or AMV-RT.
- This step typically requires temperatures from 37-75°C and times from 1-60 minutes. Following this initial template conversion step, the reactions proceed as outlined above.
- the Final Extension step often is omitted.
- the optimal temperature for Taq DNA Polymerase (and other thermostable polymerases) during the Extension step generally is between about 68-74°C.
- the Hybridization and Extension steps in Table 1 can be performed at the same temperature, simultaneously; alternatively the Extension step can be performed at a higher temperature than the Hybridization step. It is seen in Table 1 that the Extension step preferably is carried out within the temperature range of 68-72 0 C.
- this step can be carried out substantially in the same range of temperature as the Hybridization step; that is from 50°C to about 72°C depending on reaction-specific factors, particularly the polymerase or other enzyme that is used to facilitate the synthesis (primer extension) reaction during the Extension step.
- the Hybridization and Extension steps can be carried out at a temperature lower than 5O 0 C so long as such lower temperature is sufficiently stringent to produce hybridization, and consequent extended, products of desired specificity.
- Denaturation temperatures typically are less than 100 0 C but greater than 90 0 C; incubation time may be 1 second up to about 15 minutes. These temperatures and times are chosen to sufficiently denature dsDNA to produce ssDNA.
- Hybridization temperatures typically are about or less than 72 0 C but greater than 50°C, with the specific temperature selected depending on the melting temperature (T m ) of the primer(s) to provide high stringency.
- a single-stranded nucleic acid binding protein is incorporated into a primer extension reaction mixture at a low temperature (such as room temperature) that is nonstringent as to the generation of nonspecific primer extension products.
- a low temperature such as room temperature
- the effect is that despite the presence in the reaction mixture, at low temperature, of all the necessary components for successful hybridization and primer extension reactions, the formation of specific primer extension products nonetheless is improved compared to nonspecific products.
- This effect is believed to result from the SSB binding to single-stranded nucleic acids in the reaction mixture at low, nonstringent temperatures that are more permissive for nonspecific primer extension products.
- the SSB in effect sequesters the primers (which are single-stranded nucleic acids) in the reaction mixture at low, nonstringent temperatures at which these reaction mixtures typically are prepared.
- SSBs may prevent or inhibit primers from hybridizing to other single-stranded nucleic acids due to their binding to the primers to form an SSB-primer complex at low, nonstringent temperatures.
- the invention is not to be limited to either of the foregoing mechanisms, which are believed, but not certain, to be responsible in whole or in part for the observed behavior. Indeed, there may be alternative explanations as to the mechanism for the reduced generation of nonspecific primer extension products. What is evident is that the SSB(s) interacts with the primer(s) at nonstringent temperatures in some manner (e.g., through binding) so that the primers thereby are prevented, or at least inhibited, from participating in primer extension reactions at those temperatures. It further has been shown that such inhibitive interaction between SSB and the primers can be reversed through heating to an elevated temperature that is more stringent for primer-template hybridization as described more fully herein.
- the present methods are referred to by the inventors as 'primer sequestration' because the primers are believed to be (or at least the effect is as though they are) sequestered, and thus prevented or inhibited from participating in primer extension reactions at nonstringent temperatures.
- the temperature of the mixture is elevated in accordance with the amplification reaction cycle profile, e.g., as described in Table 1, to perform a desired amplification reaction.
- the SSB is selected such that at the temperature at which the reactions are to proceed (Hybridization and Extension steps in Table 1), the SSB is or becomes denatured, or otherwise ceases to interact with or becomes dissociated from the primers, as by breaking or disrupting a chemical or physical bond therebetween, thereby releasing the primers so they are free to participate in the reaction.
- temperatures 50-72°C from Table 1 are stringent compared to the temperature at which the reactions were assembled, so specific annealing is thermodynamically favored over nonspecific annealing.
- SSBs are selected which are effective to interact or associate with the primers via a thermolabile (i.e., heat-sensitive) interaction.
- This interaction is spontaneously disrupted at elevated temperatures, preferably at or near the range of more stringent yet optimal temperatures for polymerase activity (typically 50-75°C, more preferably 68-72 0 C) 3 but preferably not less than 30, preferably 37, preferably 40, preferably 50, degrees Celsius.
- the bond between the SSB and the single- stranded nucleic acid is a non-covalent bond that is sensitive to heating (i.e., above about 30°C, 4O 0 C or 5O 0 C).
- the SSBs may bind to and thereby sequester the primer molecules at a temperature at or below 30 0 C, but become denatured at an elevated temperature in the range of 30 0 C to 98°C or 50°C to 98°C (more preferably up to 96°C, more preferably up to 95°C) such that the interaction between the primer and the SSB is terminated or caused to be terminated as a result of or in conjunction with the denaturation of the SSB, thereby releasing the associated primers such that they are free to anneal to their intended targets.
- the primers are sequestered at lower, nonstringent temperatures where hybridization specificity is relatively low, but are free to form hybrids at elevated temperatures where stringency and consequently hybridization specificity are relatively high.
- any SSB or combination of SSBs may be useful in the present invention with the preferred (but not limited to) characteristics: 1) the SSB(s) binds primers at lower temperatures commonly used during assembly of PCR reactions (i.e., at, near or lower than room temperature, or between 0-30 0 C, more typically between 15-27°C); 2) the SSB(s) binds primers in commonly used or conventional PCR buffers; and 3) the SSB(s) does not bind primers at more stringent temperatures for specific hybridization (preferably at about or greater than 30, 40, 50, 60, 70, 80, or 90, degrees Celsius).
- Termination of the interaction between the SSB(s) and the primers at elevated temperatures may be due to a thermolabile bond or otherwise via denaturation of the SSB(s). This makes the primers available during the operative steps of a PCR and viable to be extended by the polymerase or polymerases in the reaction mixture.
- the SSB used in the disclosed methods is wild- type T7 SSB, a mutant variant of T7 SSB, or a combination thereof.
- Wild-type T7 SSB is also known as T7 gp2.5 or T7 gene 2.5 in the scientific literature, a term that describes its coding sequence's position in the bacteriophage T7 genome.
- the term 'wild-type' herein means the non-mutated or original DNA and protein sequence provided in publicly available databases and literature (e.g., Dunn and Studier, 1983, Journal of Molecular Biology 166(4):477-535).
- T7 SSB forms stable dimers in solution which are composed of two identical subunits that have a molecular weight 25,562 gm mol "1 each.
- T7 SSB binds with high affinity to ssDNA over dsDNA and each protein monomer binds a length of about 7 nucleotides.
- the thermostability of T7 SSB has been determined and its melting temperature (T m ) is about 53°C.
- T m melting temperature
- the melting temperature of a protein is analogous to the melting temperature of dsDNA and is defined as the transition temperature at which about 50% of the protein is completely denatured relative to its native state.
- an SSB is termed 'denatured' when it is or ceases to be effective to prevent or inhibit the generation of primer extension products according to the disclosed methods, for example because it has lost its ability to bind to single-stranded nucleic acids as by heating to unwind the protein from its native or effective conformation.
- a thorough characterization of T7 SSB is found in Kim et al., 1992, Journal of Biological Chemistry 267(21):15022-15031.
- SSBs are known to bind to single-stranded nucleic acids stoichiometrically.
- the SSB concentration provided in a reaction mixture be sufficient to produce a stoichiometric excess of SSB relative to the primers in the mixture. Determination of the stoichiometric ratio between a particular SSB and a particular primer (or primers) is well within the ability of one having ordinary skill in the art without undue experimentation, and in fact the stoichiometric ratios for numerous SSBs are known from the published literature.
- ssDNA binding proteins including the wild-type and mutant T7 SSBs discussed herein, have a binding affinity for ssDNA that is generally a few orders of magnitude greater than their affinity for dsDNA or RNA (e.g., Chase and Williams, 1986, Annual Reviews of Biochemistry 55:103-136; Lindberg et al., 1989, Journal of Biological Chemistry 264(21):12700-12708; Curth et al., 1996, Nucleic Acids Research 24(14):2706- 2711).
- dsDNA and/or RNA template amounts in the reaction are not taken into consideration. This approximation applies to most standard PCR reactions since generally dsDNA is the preferred or most common template.
- T7 SSB wild-type and mutant varieties interacts with about 7 single-stranded nucleotide bases of DNA per protein molecule (also referred to as monomer). For a primer having a length of 21 nucleotide bases, this equates to a stoichiometric ratio of 3 monomers of T7 SSB per molecule of primer. Depending on the concentration of the primer and the molecular weight of the protein, an appropriate concentration for the SSB can be determined through simple arithmetic to produce a desired stoichiometric excess of SSBs.
- the wild-type or naturally occurring T7 SSB is preferred.
- the amino acid sequence of wild- type T7 SSB is provided in the Sequence Listing as SEQ ID NO. 4; the DNA gene sequence that codes for wild-type T7 SSB also is provided as SEQ ID NO. 3.
- the mutants T7 gp2.5 ⁇ 21C (SEQ ID NO. 5), T7 gp2.5 F232L (SEQ ID NO. 7) and a mixture of wild-type and T7 gp2.5 ⁇ 26C (SEQ ID NO. 6) also have proven useful as will be shown in the following Examples, and also are preferred.
- T7 SSB mutants ⁇ 21C (SEQ ID NO. 5) and ⁇ 26C (SEQ ID NO. 6) have a deletion of the last 21 and 26 amino acids of the wild-type protein, respectively. They have been shown to bind single-stranded DNA with at least 10-fold greater affinity over the wild-type protein (e.g., T.
- certain mutant E. coli SSBs and T4 SSB also may be useful to provide a sufficient primer sequestration effect at nonstringent temperatures as described herein, e.g., through reversible interaction (such as binding) with the primers at those temperatures. It is noted that wild-type E. coli SSB has been found to be unsuitable for use in the disclosed methods because it has been shown to interfere with PCR (see Example 1). When wild-type E. coli SSB is used in stoichiometric excess over the primers, PCR amplification products are not observed.
- this SSB appears to continue to bind or interact with the primers even at the elevated, more stringent temperatures required for specific primer-template hybridization.
- a potential explanation is that it is well-known E. coli SSB retains some binding activity even after boiling for up two minutes (Chase and Williams, 1986, Annual Reviews of Biochemistry 55:103-136).
- wild-type E. coli SSB appears to be able to withstand exposure to high temperatures and its inhibitive effects on primer extension reactions are not readily thermally inactivated.
- the inventors have cloned the nucleotide sequence for, and expressed and purified protein from, wild-type and mutant forms of T7 SSB as described below.
- the following procedures are well within reasonable standards for those of ordinary skill in the art.
- the growth and purification procedures can be modified from those described below depending on the binding protein being purified as well as contaminants present in the preparation.
- T7 SSB wild-type T7 SSB gene nucleotide sequence from positions 9158-9856 in purified bacteriophage T7 genomic DNA (USB Corporation, Cleveland, Ohio).
- the complete genome sequence for T7 can be found at locus NC_001604 at the National Center for Biotechnology Information (NCBI).
- Bacteriophage T7 is publicly available from the American Type Culture Collection (ATCC) under catalog numbers 11303-B38TM and BAA-1025-B2TM.
- ATCC American Type Culture Collection
- wt T7 gp2.5 also referred to as T7 SSB
- mutant varieties thereof which are discussed herein are provided in the Sequence Listing for convenience and ease of reference.
- PCR generated DNA fragments (wild-type T7 SSB gene) were ligated into TOPOIITM vector (Invitrogen Corporation), transformed into TOP 10TM chemically competent E. coli (Invitrogen Corporation) and the resulting plasmid containing the wild-type T7 SSB gene (SEQ ID NO. 3) was selected in presence of kanamycin.
- the clone generated from PCR-amplified DNA was sequenced and found to be free of mutations. The plasmid was then cut with Ndel and Xmal and cloned into the pRE expression vector.
- This expression vector is under the control of the powerful promoter pL from the bacteriophage ⁇ which is repressed by the ⁇ repressor at 30 0 C.
- the expression from the pL containing vector is induced by raising the temperature to 42°C.
- the resulting plasmid containing T7 SSB (SEQ ED NO. 4) was selected in presence of ampicillin. All mutant forms of T7 SSB prepared herein were expressed from the base DNA clones described in this paragraph, which were first altered using reverse primers that either incorporated base changes to alter amino acids or introduced a stop codon to terminate protein synthesis at the desired location depending on the mutation to be prepared.
- the cells were incubated for 2 additional hours and then harvested by centrifugation at 6,000 rpm for 15 minutes in a Sorvall GS-3 rotor.
- the cell paste (83 gm) was then stored at -80°C.
- Ammonium Sulfate Precipitation To 400 ml of fraction II, ammonium sulfate was added to 75% saturation (203 gm) over a period of 60 minutes and was stirred slowly for an additional 60 minutes. The precipitate was collected by centrifugation at 14,000 rpm for 45 minutes in a Sorvall GSA rotor and dissolved in 50 ml of Buffer A containing 25 mM NaCl and dialyzed overnight against the same buffer (Fraction III).
- Heparin Sepharose CL-6B Chromatography A column of Heparin (0.64 cm 2 x 12 cm) was prepared and equilibrated with Buffer A containing 25 mM NaCl. Fraction III was applied to the column and eluted with a linear gradient from 25 mM to IM NaCl. The fractions were analyzed on SDS-PAGE and the fractions (134 ml) containing the T7 SSB were pooled and dialyzed overnight against Buffer A containing 100 mM NaCl (Fraction IV).
- DEAE Sephacel Chromatography A column of DEAE Sephacel (5.30 cm 2 x 12 cm) was prepared and equilibrated with Buffer A containing 100 mM NaCl. Fraction III was applied to the column and eluted with a linear gradient from 100 mM to 500 mM NaCl. The fractions were analyzed on SDS-PAGE. Fractions containing T7 SSB appeared to be homogeneous as a single band judged by electrophoresis under denaturing conditions, but contained a low level of single stranded DNA dependent nucleoside 5'- triphosphatase activity. The fractions (64ml) containing the T7 SSB were pooled and dialyzed overnight against Buffer A containing 100 mM NaCl (Fraction V).
- Protein Concentration The protein concentration was determined using the BCA Protein Determination Assay Kit (Pierce, Rockford, Illinois) against a BSA standard curve. After SDS-PAGE electrophoresis of the purified SSB protein under denaturing conditions, staining with Coomassie Blue produced a single band corresponding to a molecular weight of approximately 30,000.
- T7 SSB both wild-type and mutant varieties, prevent or inhibit primer extension reactions at lower temperatures (e.g., less than about 50°C, and particularly less than about 30 0 C) but that such inhibitive effect is lost at higher, more stringent temperatures (e.g., greater than about 50°C).
- the inventors have discovered, surprisingly and unexpectedly, that inclusion of T7 SSB and/or its mutant forms in PCR prior to the Initial Denaturation step leads to less amplification artifacts. This unexpected result is believed to occur because nonspecific priming events and/or primer extension products are not formed or are inhibited from being formed at the lower temperatures at which PCR mixtures typically are assembled or prepared.
- the primers are sequestered at temperatures where specificity tends to be low before the reaction mixture is heated, and then the primers are released and thus available for hybridization and polymerization at higher, more stringent temperatures. In this manner, it has been observed that amplification of unintended targets formed due to low hybridization specificity (at low temperature) has been substantially reduced.
- a 306 base pair (bp) region of the gene product Numb was amplified, separately, under a variety of different conditions of SSB species and concentration, selection of polymerase, etc., as further described below, from 5 nanograms (ng) of human genomic DNA.
- the target is identified as NT_026437.11 at NCBI (sequence location: 54742877 to 54743182).
- the following amplification primers were used, each of which was 25 bases in length;
- Numb Forward 5'-GAGGTTCCTACAGGCACCTGCCCAG-S' (SEQ ID NO. 9) and Numb Reverse: 5'-CAAAATCACCCCTCACAGTACTCTG-S' (SEQ ID NO. 10).
- the 15 PCR reaction mixtures had the following specific attributes: Reaction 1: antibody-bound Taq DNA Polymerase, no SSB; Reaction 2: chemically-modified Taq DNA Polymerase, no SSB; Reaction 3: unmodified Taq DNA Polymerase, no SSB; Reaction 4: 1 ⁇ g wild-type E. coli SSB, antibody-bound Taq DNA Polymerase Reaction 5: 1 ⁇ g wild-type E. coli SSB, chemically-modified Taq DNA Polymerase; Reaction 6: 1 ⁇ g wild-type E.
- Reaction 7 1 ⁇ g wild-type T7 SSB, antibody-bound Taq DNA Polymerase
- Reaction 8 1 ⁇ g wild-type T7 SSB, chemically-modified Taq DNA Polymerase
- Reaction 9 1 ⁇ g wild-type T7 SSB, unmodified Taq DNA Polymerase
- Reaction 10 1 ⁇ g ⁇ 21C T7 SSB, antibody-bound Taq DNA Polymerase
- Reaction 11 1 ⁇ g ⁇ 21C T7 SSB, chemically-modified Taq DNA Polymerase
- Reaction 12 1 ⁇ g ⁇ 21C T7 SSB, unmodified Taq DNA Polymerase
- Reaction 13 1 ⁇ g F232L T7 SSB, antibody-bound Taq DNA Polymerase
- Reaction 14 1 ⁇ g F232L T7 SSB, chemically-modified Taq DNA Polymerase
- Reaction 15 1 ⁇ g F232L T7 SSB
- Master Mix 1 was a 6X mix that contained water, PCR buffer, dNTPs, and the respective polymerase.
- Master Mix 2 was a 2OX mix that contained the human genomic DNA and primers. The components were added in the following order to the reaction tubes at room temperature; 23.5 ⁇ l of the appropriate Master Mix 1 (i.e., with respective polymerase), 0.5 ⁇ l of the SSB or SSB Storage Buffer when performing controls, and 1 ⁇ l of Master Mix 2.
- the concentration of T7 gp2.5 ⁇ 21C used in Reactions 10-12 was 0.5 mg/ml, not 2 mg/ml as in the other reaction mixtures, and thus 2 ⁇ l of this protein were added per 25 ⁇ l reaction instead of 0.5 ⁇ l to achieve the same total SSB concentration for Reactions 10-12.
- the 1OX PCR buffer consisted of 10OmM Tris-HCl (pH 8.6), 50OmM KCl, and 15mM MgCl 2 .
- the 5mM dNTP mixture contained the four deoxyribonucleotides required for DNA synthesis (dATP, dGTP, dTTP, and dCTP).
- the SSBs from T7 were prepared as described elsewhere herein.
- E. coli SSB and unmodified Taq DNA Polymerase i.e., non-hot-start
- SSBs were added to the respective reaction mixtures before the primers and template.
- the SSB storage buffer without SSBs, was added instead.
- two commercially available hot-start products were used in place of standard (unmodified) Taq DNA Polymerase, Reactions 1, 4, 7, 10, and 13 and 2, 5, 8, 11, and 14, respectively.
- the antibody-bound Taq DNA Polymerase (tradename PlatinumTM Taq DNA Polymerase) used in Reactions 1, 4, 7, 10, and 13 was from Invitrogen Corporation, Carlsbad, California.
- the chemically-modified Taq DNA Polymerase (tradename HotStarTaqTM DNA Polymerase) used in Reactions 2, 5, 8, 11, and 14 was from Qiagen Incorporated, Valencia, California.
- reaction mixtures were incubated at room temperature (i.e., 20-25°C) for a period of 30 minutes before the reactions tubes were placed in the thermal cycler. This extra time at room temperature was chosen so as to favor the generation of nonspecific products.
- reaction tubes were placed in a thermal cycler (MJ Research, Waltham, Massachusetts) with the following cycling conditions shown in Table 3 common among all the reactions except as otherwise noted: Table 3
- the Initial Denaturation time was 2 minutes for reactions containing the unmodified Taq DNA polymerase and the antibody-bound Taq DNA polymerase, and 15 minutes for the chemically-modified Taq DNA polymerase as per the manufacturer's instructions.
- This example illustrates the effectiveness of a mixture of wild-type and mutant T7 SSB in the hot-start method.
- this example uses a 1:1 mass ratio of wild-type T7 SSB to ⁇ 26C protein in a polymerase chain reaction to reduce the generation of nonspecific primer extension products.
- 1 microgram ( ⁇ g) of the mixture contained 0.5 ⁇ g of each protein.
- An 1142 base pair (bp) region of the gene product p53 (SEQ ID NO. 11) was amplified from either 1 nanogram (ng) or 100 picograms (pg) of human genomic DNA. This target is identified as NT_010718.15 at NCBI (sequence location: 7174821 to 7175962). The following amplification primers were used;
- p53 Forward 5'-TGCTTTATCTGTTCACTTGTGCCC-S' 24 bases in length (SEQ ID NO. 12)
- p53 Reverse 5'-TGTGCAGGGTGGCAAGTGGC-S' 20 bases in length (SEQ ID NO. 13).
- the 8 PCR reaction mixtures had the following specific attributes:
- Reaction 1 100 pg genomic DNA, no SSB;
- Reaction 2 0.5 ⁇ g T7 SSB mix, 100 pg genomic DNA
- Reaction 3 1.0 ⁇ g T7 SSB mix, 100 pg genomic DNA
- Reaction 4 2.0 ⁇ g T7 SSB mix, 100 pg genomic DNA
- Reaction 5 1 ng genomic DNA, no SSB;
- Reaction 6 0.5 ⁇ g T7 SSB mix, 1 ng genomic DNA
- Reaction 7 1.0 ⁇ g T7 SSB mix, 1 ng genomic DNA
- Reaction 8 2.0 ⁇ g T7 SSB mix, 1 ng genomic DNA.
- Master Mix 1 was a 1OX mix that contained water, PCR buffer, dNTPs, and Taq DNA Polymerase.
- Master Mix 2 was a 1OX mix that contained water, 100 pg/reaction human genomic DNA, and primers.
- Master Mix 3 was a 1OX mix that contained water, 1 ng/reaction human genomic DNA, and primers. It is noted that the final water volume from Table 4 was divided such that 48% of the final volume was present in mix 1 and 52% of the final volume was present in mix 2 or mix 3.
- the components were added in the following order to the reaction tubes at room temperature; 12.5 ⁇ l of Master Mix 1, 0.5 ⁇ l of the SSB, or SSB Storage Buffer when performing controls, and 12 ⁇ l of Master Mix 2 or Master Mix 3 as appropriate.
- the 1OX PCR buffer consisted of 10OmM Tris-HCl (pH 8.6), 50OmM KCl, and 15mM MgCl 2 .
- the 25mM dNTP mixture contained the four deoxyribonucleotides that are required for DNA synthesis (dATP, dGTP, dTTP, and dCTP).
- the SSBs from T7 were prepared as described elsewhere herein except the final storage buffer was changed to 2OmM Tris-HCl (pH 8.5), 20OmM KCl, ImM DTT, O.lmM EDTA, 0.5% Tween-20, and 50% glycerol.
- Serial dilutions of the SSB mixture were performed in final storage buffer in order to add 0.5 ⁇ l per reaction.
- the SSB storage buffer without any SSBs, was added instead.
- SSB was added to the reaction mixture before the primers and template.
- Serial dilutions of the human genomic DNA were performed in nuclease-free water.
- Taq DNA Polymerase was from USB Corporation, Cleveland, Ohio.
- reaction tubes were placed in a thermal cycler (MJ Research, Waltham, Massachusetts) using the cycling conditions as listed below in Table 5. It is noted that an additional pre-incubation step at 25°C for one hour was programmed into the thermal cycler so as to simulate room temperature. This extra time at 25°C was chosen so as to favor the generation of nonspecific products.
- This example further illustrates the effectiveness of mixtures of wild-type and mutant T7 SSB in blocking primer extension at room temperature.
- this example uses a 1:1 mass ratio of wild-type T7 SSB to ⁇ 26C protein in a 'mock' polymerase chain reaction in which primer extension was directed at two primers that were purposefully designed to form hybrids.
- primer extension was directed at two primers that were purposefully designed to form hybrids.
- This assay was designed to access the ability of SSB to block DNA synthesis from an extendable hybrid at two temperatures. The first temperature was room temperature (25°C), as this simulated the temperature at which reactions are generally assembled. The second was at 72°C, which is a more optimal temperature for DNA synthesis by Taq DNA Polymerase.
- the two primers chosen for this experiment were designed to form a dsDNA hybrid with 14 bp of overlap at their 3'-ends.
- the forward primer of 23 bases had a HEX fluorescent label attached to its 5 'end which enabled detection of the synthesis product on a fluorescent scanner. Since the reverse primer of 41 bases has 14 bp of overlap with the forward primer, the maximum synthesis product that could be generated from the forward primer was 50 bases. This primer extension product was visualized during denaturing polyacrylamide gel electrophoresis. A schematic of the assay is shown in Figure 3a.
- the 10 mock PCR reaction mixtures had the following specific attributes: Reaction 1 : no SSB, no Taq DNA Polymerase, 25°C incubation; Reaction 2: Taq DNA Polymerase, no SSB, 25°C incubation; Reaction 3: 0.5 ⁇ g T7 SSB mix, Taq DNA Polymerase, 25°C incubation; Reaction 4: 1.0 ⁇ g T7 SSB mix, Taq DNA Polymerase, 25°C incubation; Reaction 5: 2.0 ⁇ g T7 SSB mix, Taq DNA Polymerase, 25°C incubation; Reaction 6: no SSB, no Taq DNA Polymerase, 72°C incubation; Reaction 7: Taq DNA Polymerase, no SSB, 72 0 C incubation; Reaction 8: 0.5 ⁇ g T7 SSB mix, Taq DNA Polymerase, 72°C incubation; Reaction 9: 1.0 ⁇ g T7 SSB mix, Taq DNA Polymerase, 72°
- Master Mix 1 was a 12X mix that contained water, PCR buffer, dNTPs, and Taq DNA Polymerase.
- Master Mix 2 was a 12X mix that contained water, PCR buffer, dNTPs, but no Taq DNA Polymerase.
- Master Mix 3 was a 12X mix that contained water and primers. It is noted that the final water volume from Table 6 was divided such that 46.8% of the final volume was present in mix 1 or mix 2 and 53.2% of the final volume was present in mix 3.
- the components were added in the following order to the reaction tubes at room temperature; 5.0 ⁇ l of Master Mix 1 or Master Mix 2 as appropriate, 0.5 ⁇ l of the SSB or SSB Storage Buffer when performing controls, and 4.5 ⁇ l of Master Mix 3.
- the 1OX PCR buffer consisted of 10OmM Tris-HCl (pH 8.6), 50OmM KCl, and 15mM MgCl 2 .
- the 25mM dNTP mixture contained the four deoxyribonucleotides that are required for DNA synthesis (dATP, dGTP, dTTP, and dCTP).
- the SSBs from T7 were prepared as described elsewhere herein except the final storage buffer was changed to 2OmM Tris-HCl (pH 8.5), 20OmM KCl, ImM DTT, O.lmM EDTA, 0.5% Tween-20, and 50% glycerol.
- reaction tubes were placed in a thermal cycler (MJ Research, Waltham, Massachusetts).
- One set of identical reactions was subjected to 25°C for four hours to over-estimate the amount of time required to assemble PCR reactions.
- the other identical set was subjected to 15 cycles at 25°C for 15 seconds and 72°C for 15 seconds to provide ideal synthesis conditions for Taq DNA Polymerase and to determine if the SSBs were still inhibitory.
- the reactions were stored at 4°C or on ice until required.
- 0.5 ⁇ l (0.05 pmol of each primer) of each reaction were electrophoresed on a 15% (29:1) denaturing polyacrylamide gel with 42% urea.
- the gel was cast with lmm spacers in IX GTG buffer (USB Corporation, Cleveland, Ohio) and run at a constant power of 6 watts per gel until a tracer dye (Bromo-cresol Green) had run about 75% the length of the gel (about 25 minutes).
- the primer extension reaction products were visualized using a fluorescent scanner (Hitachi FMBIO II, San Francisco, California).
- This example illustrates a useful range of effective concentrations of T7 SSB that achieve the desired effect of reducing the generation of nonspecific primer extension products.
- the following experiment was designed taking into account both a) the stoichiometric binding ratio of T7 SSB of 7 nucleotides bound per protein monomer, and b) the total amount of primers (ssDNA) in a given reaction.
- the experiment was an amplification of the Numb target of 306 bp from 1 ng of human genomic DNA that was used in Example 1.
- the primers were each 25 bases in length as follows: Numb Forward: 5'-GAGGTTCCTACAGGCACCTGCCCAG-S' (SEQ ID NO.
- Reaction 5 0.5 ⁇ g wild-type T7 SSB
- Reaction 7 2.0 ⁇ g wild-type T7 SSB.
- Master Mix 1 was a 1OX mix that contained water, PCR buffer, dNTPs, and Taq DNA Polymerase.
- Master Mix 2 was a 1OX mix that contained water, 1 ng/reaction human genomic DNA, and primers. It is noted that the final water volume from Table 7 was divided such that 48% of the final volume was present in mix 1 and 52% of the final volume was present in mix 2. The components were added in the following order to the reaction tubes at room temperature; 12.5 ⁇ l of Master Mix 1, 0.5 ⁇ l of the SSB or SSB Storage Buffer when performing controls, and 12 ⁇ l of Master Mix 2.
- the 1OX PCR buffer consisted of 10OmM Tris-HCl (pH 8.6), 50OmM KCl 5 and 15mM MgCl 2 .
- the 25mM dNTP mixture contained the four deoxyribonucleotides that are required for DNA synthesis (dATP, dGTP, dTTP, and dCTP).
- Wild-type T7 SSB was prepared as described elsewhere herein except the final storage buffer was changed to 2OmM Tris-HCl (pH 8.5), 20OmM KCl, ImM DTT, O.lmM EDTA, 0.5% Tween-20, and 50% glycerol.
- Serial dilutions of the wild-type T7 SSB were performed in final storage buffer in order to add 0.5 ⁇ l per reaction.
- the SSB storage buffer, without any SSBs, was added instead.
- SSB was added to the reaction mixture before the primers and template.
- Taq DNA Polymerase was from USB Corporation, Cleveland, Ohio.
- each reaction contained 5 picomoles (pmol) of each primer and therefore a relatively simple calculation could be performed to determine the molar amount of single- stranded DNA binding sites in the reaction. Since the primers were each 25 bases in length and T7 SSB binds about 7 nucleotides per protein monomer, each primer had about 3.57 binding sites. Given there were 10 pmol total primers in each reaction x 3.57 binding sites per primer meant there were roughly 36 pmol total ssDNA binding sites in each reaction. The mass amount of wild-type T7 SSB varied in this experiment, serially-doubling from 62.5 ng per reaction to 2 ⁇ g per reaction.
- T7 SSB is 25,562 gm per mol per monomer
- Table 8 could be constructed showing the molar amount of T7 SSB monomers in each reaction condition as well as the molar ratio of T7 SSB to total available binding sites in each reaction condition.
- reaction tubes were placed in a thermal cycler (MJ Research, Waltham, Massachusetts) using the cycling conditions as listed below in Table 9. It is noted that an additional pre-incubation step at 25 °C for one hour was programmed into the thermal cycler so as to simulate room temperature. This extra time at 25 °C was chosen so as to favor the generation of nonspecific products.
- primer sequestration method described herein is that it will work with any polymerase because the SSB interacts with and acts to inhibit the primers, and does not depend on any interaction with a particular polymerase.
- the antibody and chemical methods discussed in the BACKGROUND section require modifications to individual polymerases. There are at least 10 different polymerases commonly used for PCR, and thus the present invention has much broader utility.
- the methods disclosed herein permit the complete reaction system, including all of the reagents necessary to carry out multiple cycles of hybridization and primer extension reactions, to be completely assembled at nonstringent temperatures (such as room temperature), without the need to subsequently add a polymerase or any other component to the reaction mixture, thus risking contamination of the reactions.
- SSBs can be incorporated into other reaction mixtures for duplicating a template nucleic acid via primer-template hybridization and extension reactions to inhibit or prevent nonspecific primer extension products where it is convenient to combine all the components necessary for both reactions at nonstringent temperatures.
- " [011 lJ Also provided is a storage buffer solution useful for long-term storage of the SSBs useful in the disclosed methods (preferably up to one year) so that they do not lose their functional activity; i.e., their ability to effectively sequester primers or prevent or inhibit the generation of nonspecific primer extension products according to methods described herein.
- the storage buffer solution preferably has the following components listed in Table 10. It is noted in Table 10, any concentration or range for any one component can be combined with ; Dncentration or range for any other component to provide the buffer solution; it is not necessary that all concentrations or ranges come from the same column.
- a suitable storage buffer can be prepared for, e.g., wild-type T7 gp2.5 using no salt, i.e., no sodium chloride. This was a particularly surprising and unexpected result, as it ordinarily would have been expected that to prevent the SSB from precipitating out of solution, a quantity of salt, such as sodium chloride, would be required. Generally, it is preferred nevertheless to provide the buffer solution with 10 mM salt concentration. For the T7 gp2.5- ⁇ 21C mutant disclosed above, a somewhat higher salt concentration is desirable to sustain me mutant in solution (i.e., prevent its precipitation), and preferably greater than 50 mM salt concentration is used.
- the buffer solution disclosed herein has the advantages the SSBs remain stable and functionally active (capable to inhibit primer hybridization at non-stringent temperatures) when stored therein for extended periods, preferably at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, months, and the residual storage buffer solution that is delivered to the PCR reaction tube along with the SSBs does not adversely affect PCR amplification reactions when using a range of polymerases.
- a liquid formulation composed of an SSB, e.g., wild-type T7gp2.5, in a buffer solution as described above has a total protein concentration ranging from 1 ⁇ g/ml to 200 mg/ml, more preferably 10 ⁇ g/ml to 100 mg/ml, even more preferably 100 ⁇ g/ml to 50 mg/ml and most preferably between 1 mg and 5 mg/ml.
- the resulting formulation of wild-type T7 gp2.5 (or other) binding protein in the above-described storage buffer has a pH between 4.0 and 12.0, more preferably between pH 6.0 and 10.0, even more preferably between 7.0 and 9.0 and most preferably pH 7.5 ⁇ 0.2.
- Table 11 below describes preferred compositions for a formulation of SSB in a storage buffer which can include further or additional additives or components beyond those described above.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05764400A EP1778866B1 (en) | 2004-06-30 | 2005-06-30 | Novel hot start nucleic acid amplification |
CA002569394A CA2569394A1 (en) | 2004-06-30 | 2005-06-30 | Novel hot start nucleic acid amplification |
JP2007519541A JP5020074B2 (en) | 2004-06-30 | 2005-06-30 | New hot start nucleic acid amplification method |
AT05764400T ATE527380T1 (en) | 2004-06-30 | 2005-06-30 | NEW HOT START NUCLEIC ACID AMPLIFICATION |
NO20065470A NO20065470L (en) | 2004-06-30 | 2006-11-28 | New hot start nucleic acid amplification. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58436204P | 2004-06-30 | 2004-06-30 | |
US60/584,362 | 2004-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006005074A2 true WO2006005074A2 (en) | 2006-01-12 |
WO2006005074A3 WO2006005074A3 (en) | 2008-06-19 |
Family
ID=35783411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/023824 WO2006005074A2 (en) | 2004-06-30 | 2005-06-30 | Novel hot start nucleic acid amplification |
Country Status (7)
Country | Link |
---|---|
US (3) | US7700281B2 (en) |
EP (2) | EP1778866B1 (en) |
JP (1) | JP5020074B2 (en) |
AT (1) | ATE527380T1 (en) |
CA (1) | CA2569394A1 (en) |
NO (1) | NO20065470L (en) |
WO (1) | WO2006005074A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8361753B2 (en) | 2006-06-01 | 2013-01-29 | Trilink Biotechnologies, Inc. | Phosphotriester-modified oligonucleotide primers for nucleic acid amplification |
US9187781B2 (en) | 2009-04-20 | 2015-11-17 | Olympus Corporation | Polymorphism identification method |
US11572580B2 (en) | 2017-06-07 | 2023-02-07 | Takara Bio Inc. | Oligonucleotide preservation method |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700281B2 (en) * | 2004-06-30 | 2010-04-20 | Usb Corporation | Hot start nucleic acid amplification |
EP2183380B1 (en) | 2007-08-27 | 2014-11-26 | Life Technologies Corporation | Methods and compositions for pcr |
JP5843614B2 (en) | 2009-01-30 | 2016-01-13 | オックスフォード ナノポア テクノロジーズ リミテッド | Adapters for nucleic acid constructs in transmembrane sequencing |
KR101162422B1 (en) * | 2009-11-30 | 2012-07-10 | 박수민 | Composition for amplifying nucleic acid |
CN106974699B (en) | 2011-04-06 | 2019-07-09 | 德普伊新特斯产品有限责任公司 | The device assembly of implantation amendment hip prosthesis |
CA2843136C (en) | 2011-07-25 | 2020-12-29 | Oxford Nanopore Technologies Limited | Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores |
WO2013185081A1 (en) * | 2012-06-08 | 2013-12-12 | Ionian Technologies, Inc | Nucleic acid amplifications |
KR20230074845A (en) | 2012-06-14 | 2023-05-31 | 라이프 테크놀로지스 코포레이션 | Novel compositions, methods and kits for polymerase chain reaction (pcr) |
EP2875154B1 (en) * | 2012-07-19 | 2017-08-23 | Oxford Nanopore Technologies Limited | SSB method for characterising a nucleic acid |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
CN111748607A (en) | 2012-08-14 | 2020-10-09 | 10X基因组学有限公司 | Microcapsule compositions and methods |
US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP3567116A1 (en) | 2012-12-14 | 2019-11-13 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
CA2900543C (en) | 2013-02-08 | 2023-01-31 | 10X Genomics, Inc. | Partitioning and processing of analytes and other species |
CA2901545C (en) | 2013-03-08 | 2019-10-08 | Oxford Nanopore Technologies Limited | Use of spacer elements in a nucleic acid to control movement of a helicase |
GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
MX2016013156A (en) | 2014-04-10 | 2017-02-14 | 10X Genomics Inc | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same. |
KR102531677B1 (en) | 2014-06-26 | 2023-05-10 | 10엑스 제노믹스, 인크. | Methods of analyzing nucleic acids from individual cells or cell populations |
EP3212807B1 (en) | 2014-10-29 | 2020-09-02 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequencing |
US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
MX367432B (en) | 2015-01-12 | 2019-08-08 | 10X Genomics Inc | Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same. |
KR20170119710A (en) | 2015-02-24 | 2017-10-27 | 10엑스 제노믹스, 인크. | Targeted nucleic acid sequence coverage method |
WO2016137973A1 (en) | 2015-02-24 | 2016-09-01 | 10X Genomics Inc | Partition processing methods and systems |
PT3882357T (en) | 2015-12-04 | 2022-09-05 | 10X Genomics Inc | Methods and compositions for nucleic acid analysis |
LT3402880T (en) | 2016-01-15 | 2024-03-12 | Thermo Fisher Scientific Baltics Uab | Thermophilic dna polymerase mutants |
WO2017197338A1 (en) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
WO2018140966A1 (en) | 2017-01-30 | 2018-08-02 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
SG11201901822QA (en) | 2017-05-26 | 2019-03-28 | 10X Genomics Inc | Single cell analysis of transposase accessible chromatin |
US10400235B2 (en) | 2017-05-26 | 2019-09-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
EP3645710A1 (en) | 2017-06-26 | 2020-05-06 | Thermo Fisher Scientific Baltics Uab | Thermophilic dna polymerase mutants |
CN111051523B (en) | 2017-11-15 | 2024-03-19 | 10X基因组学有限公司 | Functionalized gel beads |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
EP3775271A1 (en) | 2018-04-06 | 2021-02-17 | 10X Genomics, Inc. | Systems and methods for quality control in single cell processing |
GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
KR102529958B1 (en) * | 2021-01-18 | 2023-05-08 | 가톨릭대학교 산학협력단 | PCR additive composition for quantitative amplification of low GC content DNA |
CN116004776A (en) * | 2022-08-30 | 2023-04-25 | 上海伯杰医疗科技股份有限公司 | One-tube RT-qPCR full-premix reaction reagent, application and RT-qPCR method |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61502282A (en) | 1984-06-01 | 1986-10-09 | ナショナル・バイオメディカル・リサ−チ・ファウンデ−ション | Nucleic acid hybridization method using catalytic action using enzymes |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4994372A (en) | 1987-01-14 | 1991-02-19 | President And Fellows Of Harvard College | DNA sequencing |
WO1991006679A1 (en) | 1989-10-24 | 1991-05-16 | Stratagene | An improved method for hybridizing nucleic acids using single-stranded nucleic acid binding protein |
US5605824A (en) * | 1989-10-24 | 1997-02-25 | Stratagene | Composition for hybridizing nucleic acids using single-stranded nucleic acid binding protein |
US5646019A (en) * | 1989-10-24 | 1997-07-08 | Stratagene | Method for producing primed nucleic acid templates |
US5449603A (en) * | 1989-10-24 | 1995-09-12 | Stratagene | Method for hybridizing nucleic acids using single-stranded nucleic acid binding protein |
CA2075050C (en) * | 1990-02-16 | 1998-10-06 | Will Bloch | Specificity and convenience of the polymerase chain reaction |
US5223414A (en) * | 1990-05-07 | 1993-06-29 | Sri International | Process for nucleic acid hybridization and amplification |
CA2218875C (en) | 1991-07-23 | 2000-11-07 | The Research Foundation Of State University Of New York | Improvements in the in situ pcr |
EP0672177B1 (en) * | 1992-01-28 | 2006-07-19 | President And Fellows of Harvard College | Method for nucleic acid hybridization using single-stranded dna binding protein |
US5338671A (en) * | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
US5364790A (en) * | 1993-02-16 | 1994-11-15 | The Perkin-Elmer Corporation | In situ PCR amplification system |
US5773258A (en) * | 1995-08-25 | 1998-06-30 | Roche Molecular Systems, Inc. | Nucleic acid amplification using a reversibly inactivated thermostable enzyme |
US5854033A (en) * | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
EP0869187A3 (en) | 1997-02-24 | 2001-02-28 | Becton, Dickinson and Company | Replication of nucleic acids using single-strand DNA binding proteins |
US6124120A (en) * | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
US6183998B1 (en) * | 1998-05-29 | 2001-02-06 | Qiagen Gmbh Max-Volmer-Strasse 4 | Method for reversible modification of thermostable enzymes |
GB9920194D0 (en) * | 1999-08-27 | 1999-10-27 | Advanced Biotech Ltd | A heat-stable thermostable DNA polymerase for use in nucleic acid amplification |
WO2003008624A2 (en) * | 2001-07-15 | 2003-01-30 | Keck Graduate Institute | Nucleic acid amplification using nicking agents |
US7399590B2 (en) * | 2002-02-21 | 2008-07-15 | Asm Scientific, Inc. | Recombinase polymerase amplification |
JP2006522582A (en) * | 2002-09-05 | 2006-10-05 | インヴィトロジェン コーポレーション | Compositions and methods for synthesizing nucleic acids |
US7282328B2 (en) * | 2002-09-20 | 2007-10-16 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
JP2004113108A (en) * | 2002-09-26 | 2004-04-15 | Aisin Seiki Co Ltd | Method for collecting dna |
JP2005110621A (en) * | 2003-10-10 | 2005-04-28 | Aisin Seiki Co Ltd | Method for amplifying nucleic acid and reagent kit for amplifying nucleic acid |
US7759057B2 (en) * | 2004-02-04 | 2010-07-20 | Ut-Battelle, Llc | Method for analyzing microbial communities |
US7700281B2 (en) * | 2004-06-30 | 2010-04-20 | Usb Corporation | Hot start nucleic acid amplification |
-
2005
- 2005-06-29 US US11/171,008 patent/US7700281B2/en active Active
- 2005-06-30 WO PCT/US2005/023824 patent/WO2006005074A2/en active Application Filing
- 2005-06-30 EP EP05764400A patent/EP1778866B1/en active Active
- 2005-06-30 EP EP11163362A patent/EP2366802A1/en not_active Withdrawn
- 2005-06-30 CA CA002569394A patent/CA2569394A1/en not_active Abandoned
- 2005-06-30 AT AT05764400T patent/ATE527380T1/en not_active IP Right Cessation
- 2005-06-30 JP JP2007519541A patent/JP5020074B2/en not_active Expired - Fee Related
-
2006
- 2006-11-28 NO NO20065470A patent/NO20065470L/en not_active Application Discontinuation
-
2007
- 2007-11-14 US US11/939,820 patent/US7951534B2/en active Active
-
2011
- 2011-03-29 US US13/074,752 patent/US8404443B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of EP1778866A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8361753B2 (en) | 2006-06-01 | 2013-01-29 | Trilink Biotechnologies, Inc. | Phosphotriester-modified oligonucleotide primers for nucleic acid amplification |
US9187781B2 (en) | 2009-04-20 | 2015-11-17 | Olympus Corporation | Polymorphism identification method |
US11572580B2 (en) | 2017-06-07 | 2023-02-07 | Takara Bio Inc. | Oligonucleotide preservation method |
Also Published As
Publication number | Publication date |
---|---|
US7700281B2 (en) | 2010-04-20 |
NO20065470L (en) | 2007-01-26 |
JP5020074B2 (en) | 2012-09-05 |
US20110189736A1 (en) | 2011-08-04 |
EP1778866A4 (en) | 2009-06-03 |
US20060029952A1 (en) | 2006-02-09 |
EP1778866A2 (en) | 2007-05-02 |
CA2569394A1 (en) | 2006-01-12 |
JP2008516584A (en) | 2008-05-22 |
WO2006005074A3 (en) | 2008-06-19 |
ATE527380T1 (en) | 2011-10-15 |
US8404443B2 (en) | 2013-03-26 |
US7951534B2 (en) | 2011-05-31 |
EP1778866B1 (en) | 2011-10-05 |
US20080138878A1 (en) | 2008-06-12 |
EP2366802A1 (en) | 2011-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1778866B1 (en) | Novel hot start nucleic acid amplification | |
JP4718493B2 (en) | Composition based on dUTP for reducing primer aggregate formation during nucleic acid amplification | |
EP0669401B1 (en) | Amplification of long nucleic acid sequences by PCR | |
US20110059868A1 (en) | Process for amplifying nucleic acids | |
US20090130720A1 (en) | Methods and kits for reducing non-specific nucleic acid amplification | |
EP1876246A1 (en) | Self-complementary primers used in LAMP gene amplification method | |
US5605824A (en) | Composition for hybridizing nucleic acids using single-stranded nucleic acid binding protein | |
WO2009155464A2 (en) | Mutated and chemically modified thermally stable dna polymerases | |
WO1991006679A1 (en) | An improved method for hybridizing nucleic acids using single-stranded nucleic acid binding protein | |
EP2151506A1 (en) | Method of amplifying target nucleic acid sequence by multiple displacement amplification including thermal cycling | |
US8058032B2 (en) | Method for amplifying unknown DNA sequence adjacent to known sequence | |
US8507662B2 (en) | Methods and kits for reducing non-specific nucleic acid amplification | |
EP2496712A1 (en) | Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase | |
WO2000073486A1 (en) | Target amplification of nucleic acid with mutant rna polymerase | |
WO2002090538A1 (en) | Method of synthesizing nucleic acid | |
JP4942160B2 (en) | Method for isothermal amplification of nucleic acid using RecA protein | |
JP3602550B2 (en) | DNA sequence amplification method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2569394 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007519541 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005764400 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005764400 Country of ref document: EP |